Literature DB >> 12213722

Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice.

Sofia Jormsjö1, Dirk M Wuttge, Allan Sirsjö, Carl Whatling, Anders Hamsten, Sten Stemme, Per Eriksson.   

Abstract

Several groups of proteolytic enzymes are able to degrade components of the extracellular matrix. During atherosclerosis, matrix remodeling is believed to influence the migration and proliferation of cells within the plaque. In the present study, gene expression of several proteases and their inhibitors was analyzed during the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice. Quantitative real-time polymerase chain reaction was used to study gene expression of proteases after 10 and 20 weeks in ApoE-/- and C57BL/6 mice and in atherosclerotic lesions and nonaffected regions of the same ApoE-/- mouse. Some of the differentially expressed proteolytic enzymes were studied by immunohistochemistry. The matrix metalloproteinase (MMP)-9 and its inhibitor TIMP-1 were differentially expressed and the expression increased with time. Urokinase-type plasminogen activator showed no major expression. In contrast, cathepsins B, D, L, and S all showed strong and increased expression in ApoE-/- mice compared to C57BL/6 mice whereas the expression of their inhibitor, cystatin C, did not differ between the two mouse strains. The expression of cathepsins was mainly localized to the lesions and not to nonaffected regions of the aorta of ApoE-/- mice. Furthermore, cathepsin expression was similar to the expression of the macrophage marker macrosialin (CD68) although expression of cathepsins B, D, and L could be demonstrated in healthy C57BL/6 mice and in nonaffected vessel segments of atherosclerotic ApoE-/- mice. Cathepsin S mRNA expression was restricted to lesions of ApoE-/- mice. Furthermore, cathepsin S was the only cathepsin that was expressed in the media and absent in lipid-rich regions. All cathepsins studied showed intimal expression, the degree and localization of which differed between individual cathepsins. In conclusion, increased expression of several cathepsins in atherosclerotic lesions suggests that these proteases may participate in the remodeling of extracellular matrix associated with the atherosclerotic process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213722      PMCID: PMC1867264          DOI: 10.1016/S0002-9440(10)64254-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

Review 1.  Emerging roles for cysteine proteases in human biology.

Authors:  H A Chapman; R J Riese; G P Shi
Journal:  Annu Rev Physiol       Date:  1997       Impact factor: 19.318

2.  Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation.

Authors:  W Li; X M Yuan; A G Olsson; U T Brunk
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-02       Impact factor: 8.311

Review 3.  Molecular regulation, membrane association and secretion of tumor cathepsin B.

Authors:  B A Frosch; I Berquin; M R Emmert-Buck; K Moin; B F Sloane
Journal:  APMIS       Date:  1999-01       Impact factor: 3.205

4.  Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima.

Authors:  V V Tertov; A N Orekhov
Journal:  Exp Mol Pathol       Date:  1997       Impact factor: 3.362

5.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.

Authors:  P Carmeliet; L Moons; R Lijnen; M Baes; V Lemaître; P Tipping; A Drew; Y Eeckhout; S Shapiro; F Lupu; D Collen
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

6.  Cathepsin S activity regulates antigen presentation and immunity.

Authors:  R J Riese; R N Mitchell; J A Villadangos; G P Shi; J T Palmer; E R Karp; G T De Sanctis; H L Ploegh; H A Chapman
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

7.  Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells.

Authors:  G K Sukhova; G P Shi; D I Simon; H A Chapman; P Libby
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

8.  Cathepsin D and cathepsin L activities in aortic aneurysm wall and parietal thrombus.

Authors:  M Gacko; S Glowiński
Journal:  Clin Chem Lab Med       Date:  1998-06       Impact factor: 3.694

9.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

Authors:  Z S Galis; G K Sukhova; M W Lark; P Libby
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

10.  Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages.

Authors:  V Y Reddy; Q Y Zhang; S J Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more
  25 in total

1.  Levels of cathepsins in acute myocardial infarction.

Authors:  Kavita K Shalia; Manoj R Mashru; Vinod K Shah; Surendra L Soneji; Satchidanand Payannavar
Journal:  Indian Heart J       Date:  2012 May-Jun

2.  Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3.

Authors:  Xian Wu Cheng; Masafumi Kuzuya; Kae Nakamura; Qun Di; Zexuan Liu; Takeshi Sasaki; Shigeru Kanda; Hai Jin; Guo-Ping Shi; Toyoaki Murohara; Mitsuhiro Yokota; Akihisa Iguchi
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 3.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

4.  Cathepsin S cannibalism of cathepsin K as a mechanism to reduce type I collagen degradation.

Authors:  Zachary T Barry; Manu O Platt
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

5.  Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.

Authors:  Christopher D Payne; Mark A Deeg; Melanie Chan; Lai Hock Tan; Elizabeth Smith LaBell; Tong Shen; David J DeBrota
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

6.  Estimating the mutational load for cardiovascular diseases in Pakistani population.

Authors:  Muhammad Shakeel; Muhammad Irfan; Ishtiaq Ahmad Khan
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

7.  Correlation between cathepsin D serum concentration and carotid intima-media thickness in hemodialysis patients.

Authors:  Seyed Adel Moallem; Fatemeh Nazemian; Sepideh Eliasi; Seyed Ali Alamdaran; Jamal Shamsara; Amir Hooshang Mohammadpour
Journal:  Int Urol Nephrol       Date:  2010-04-13       Impact factor: 2.370

8.  Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis.

Authors:  Dler Faieeq Darweesh Mahmood; Imene Jguirim-Souissi; El-Hadri Khadija; Nicolas Blondeau; Vimala Diderot; Souliman Amrani; Mohamed-Naceur Slimane; Tatiana Syrovets; Thomas Simmet; Mustapha Rouis
Journal:  J Biol Chem       Date:  2011-06-23       Impact factor: 5.157

Review 9.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

Review 10.  Innate and adaptive immunity in atherosclerosis.

Authors:  René R S Packard; Andrew H Lichtman; Peter Libby
Journal:  Semin Immunopathol       Date:  2009-05-16       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.